This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ESMO, Barcelona, Spain 26-30 September 2019

Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours

Nicolas Girard, Björn Hackanson, Martin Wermke, Fabrice Barlesi, Harald Timotheus Landsteiner, Girish Jayadeva, Jürgen Alt

Girard 1336.11 Tip Poster

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

FOR HEALTHCARE PROFESSIONALS ONLY

image